WCLC24: Rybrevant-Lazcluze Combination Shows Enhanced Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC
Rybrevant, Lazcluze, Tagrisso, EGFR-mutated NSCLC, MARIPOSA study, WCLC24, survival benefit, first-line treatment.
AstraZeneca Refines NSCLC Treatment Strategies with Biomarker-Driven Approaches
NSCLC, biomarkers, targeted therapy, immunotherapy, AstraZeneca, lung cancer treatment
WCLC24 Highlights: ArriVent’s Drug Aims to Address Tagrisso’s Limitations; Boehringer and Bayer Share Data on HER2-Mutated Lung Cancer
WCLC24, ArriVent, Tagrisso, Boehringer, Bayer, HER2-mutated lung cancer, Lung cancer treatment, EGFR-mutated lung cancer
Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer
Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck
AstraZeneca’s IL-33 Drug Shows Mixed Results in COPD Trials, Despite Phase 2 Setbacks
AstraZeneca, IL-33, COPD, tozorakimab, phase 2 trials, respiratory diseases
Terns Pharmaceuticals’ Oral GLP-1 Drug Demonstrates Promising Weight Loss Results
Terns Pharmaceuticals, Oral GLP-1, Weight Loss, Obesity Treatment, TERN-601
Superluminal Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials
Superluminal, Eli Lilly, Series A funding, membrane receptor drugs, clinical trials, biotech, pharmaceuticals